Glioblastoma Study
Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter - a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone (CENTRIC).
Protocol ID
08-06-234
Protocol Description
The primary purpose of this study is to expand researchers' knowledge of whether an experimental drug, cilengitide, when used in addition to the standard care (radiation therapy and chemotherapy with temozolomide) is safe and effective for the treatment of glioblastoma.
Other purposes of this study include:
- Looking at the effect of cilengitide on progression of brain cancer,
- Obtaining information on the safety and effectiveness of cilengitide when it is used in combination with standard care,
- Looking at whether certain tests of a patients' blood and tumor tissue can predict how well glioblastoma may respond to the study drugs,
- Measuring patient quality of life during the study.
Eligibility Criteria
Patients with glioblastoma
Primary Investigator(s)
- Michael Schulder, MD